Sascha Meyer, Johannes Bay, Axel R Franz, Harald Erhardt, Lars Klein, Jutta Petzinger, Christoph Binder, Susanne Kirschenhofer, Anja Stein, Britta Hüning, Axel Heep, Eva Cloppenburg, Julia Muyimbwa, Torsten Ott, Julia Sandkötter, Norbert Teig, Susanne Wiegand, Michael Schroth, Andrea Kick, Donald Wurm, Corinna Gebauer, Knud Linnemann, Jochen Kittel, Christian Wieg, Ursula Kiechl-Kohlendorfer, Susanne Schmidt, Ralf Böttger, Wolfgang Thomas, Francisco Brevis Nunez, Antje Stockmann, Thomas Kriebel, Andreas Müller, Daniel Klotz, Patrick Morhart, Donatus Nohr, Hans Konrad Biesalski, Eleni Z Giannopoulou, Susanne Hilt, Martin Poryo, Stefan Wagenpfeil, Nadja Haiden, Christian Ruckes, Anne Ehrlich, Ludwig Gortner
BACKGROUND: Vitamin A plays a key role in lung development, but there is no consensus regarding the optimal vitamin A dose and administration route in extremely low birthweight (ELBW) infants. We aimed to assess whether early postnatal additional high-dose fat-soluble enteral vitamin A supplementation versus placebo would lower the rate of moderate or severe bronchopulmonary dysplasia or death in ELBW infants receiving recommended basic enteral vitamin A supplementation. METHODS: This prospective, multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial conducted at 29 neonatal intensive care units in Austria and Germany assessed early high-dose enteral vitamin A supplementation (5000 international units [IU]/kg per day) or placebo (peanut oil) for 28 days in ELBW infants...
April 18, 2024: Lancet Respiratory Medicine